Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

The conversation discusses using a 0.03% topical Dutasteride solution for hair loss, as it may be more effective than Finasteride with fewer systemic side effects. OP plans to apply it daily for 100 days, then reduce frequency, due to past negative cognitive effects from oral treatments.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

A 43-year-old male has been using oral minoxidil, finasteride, and dutasteride for hair loss, with some stabilization and thin hair growth but no significant cosmetic improvement. He is considering increasing microneedling frequency and exploring other options, as he is concerned about the lack of terminal hair growth.

A user experienced significant hair loss after starting microneedling, despite using dutasteride and topical minoxidil. They are advised to consult a doctor as the shedding pattern is unusual and may indicate alopecia areata or other scalp conditions.

The conversation discusses concerns about RU58841 degrading when exposed to light and transferring pyri to a dark glass bottle to prevent this. The user keeps the pyri out for only two minutes before storing it in a dark place.

Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.

Genetics mainly cause hair loss, but diet, stress, smoking, and alcohol can worsen it. Treatments include finasteride, minoxidil, and lifestyle changes like a healthy diet and avoiding caffeine.

The user has been using finasteride and topical minoxidil for 15 months but is experiencing constant hair shedding, similar to telogen effluvium, despite stable widow peaks. They have checked for vitamin and mineral deficiencies, consulted specialists, and are considering further investigation like a scalp biopsy.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

A woman experiencing hormonal hair loss is on dutasteride and bicalutamide, which initially improved her hair, but she is now experiencing a second shedding phase with significant short hair loss. Despite normal hormone levels and no deficiencies, she is unsure if this shedding is normal and seeks advice.

The user discusses their experience with diffuse unpatterned alopecia and acquired progressive hair kinkering, noting improvements with treatments including biotin, pantothenic acid, finasteride, ketoconazole, and zinc pyrithione shampoo. They report thicker, healthier hair and improved scalp condition, attributing success mainly to biotin, pantothenic acid, and finasteride.

Microneedling before applying topical finasteride or dutasteride may enhance their effectiveness by increasing local absorption in the scalp, despite concerns about systemic absorption. Users discuss combining this method with oral treatments and minoxidil, noting potential benefits and side effects.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

PP405 is being discussed as a potential new approach to hair loss by targeting follicle stem cells, suggesting a different mechanism from existing treatments like finasteride and minoxidil. However, there is skepticism about whether it will lead to meaningful long-term outcomes or follow the pattern of previous treatments that showed promise but lacked consistent results.

A user experiences a whitish residue buildup on their temples from using a compounded minoxidil and finasteride spray. Suggestions include ensuring a clean scalp before application, adjusting timing, using a moisturizer, and considering oral treatments to avoid residue.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

The conclusion of the conversation is that experiencing shedding while using finasteride and minoxidil is a common occurrence, and it is likely a part of the hair growth cycle. Many users have reported regrowth and improvement in their hair density after the shedding phase.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

To increase hair density appearance, options include using hair fibers, volume powders, scalp micropigmentation, and a combination of sea salt and holding sprays. Tape-in extensions and clip-in fringes are also considered, but cost and maintenance are concerns.

The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.

The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.

The conversation discusses the potential of PP405 as a hair loss treatment, with some users expressing skepticism and others hopeful about its development. There is also mention of other treatments like Minoxidil, Finasteride, and Pyrilutamide, with users debating the effectiveness and safety of self-experimentation versus waiting for clinical trial results.

Concerns about the potential high cost of new hair loss treatments, pp405 and gt20029, were discussed, with some users willing to pay a premium if they are effective. Alternatives like finasteride and minoxidil are mentioned as current, more affordable options, and there is speculation about future generic versions and black market availability.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.

The conversation discusses skepticism and diminishing excitement around the hair loss treatment PP405 due to unclear trial results. It also mentions other treatments like finasteride, minoxidil, VDPHL01 (extended-release minoxidil), and GT20026 as potential options for hair loss management.

Pelage executives' hairlines were discussed, with speculation about them using PP405 for hair regrowth. Concerns were raised about using untested drugs, with some suggesting executives might not risk using them without safety data.